- Home
- OTLK vs MGN Comparison
OTLK vs MGN Comparison
Compare OTLK & MGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- MGN
- Stock Information
- Founded
- OTLK 2010
- MGN 2020
- Country
- OTLK United States
- MGN Malaysia
- Employees
- OTLK N/A
- MGN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- MGN
- Sector
- OTLK Health Care
- MGN
- Exchange
- OTLK Nasdaq
- MGN Nasdaq
- Market Cap
- OTLK 42.8M
- MGN 43.0M
- IPO Year
- OTLK 2016
- MGN 2025
- Fundamental
- Price
- OTLK $1.46
- MGN N/A
- Analyst Decision
- OTLK Buy
- MGN
- Analyst Count
- OTLK 5
- MGN 0
- Target Price
- OTLK $5.25
- MGN N/A
- AVG Volume (30 Days)
- OTLK 2.5M
- MGN 930.4K
- Earning Date
- OTLK 08-14-2025
- MGN 10-28-2025
- Dividend Yield
- OTLK N/A
- MGN N/A
- EPS Growth
- OTLK N/A
- MGN N/A
- EPS
- OTLK N/A
- MGN 0.07
- Revenue
- OTLK $1,505,322.00
- MGN $13,484,571.00
- Revenue This Year
- OTLK N/A
- MGN N/A
- Revenue Next Year
- OTLK $313.69
- MGN N/A
- P/E Ratio
- OTLK N/A
- MGN $35.18
- Revenue Growth
- OTLK N/A
- MGN N/A
- 52 Week Low
- OTLK $0.79
- MGN $2.23
- 52 Week High
- OTLK $6.98
- MGN $8.63
- Technical
- Relative Strength Index (RSI)
- OTLK 62.88
- MGN N/A
- Support Level
- OTLK $1.18
- MGN N/A
- Resistance Level
- OTLK $1.30
- MGN N/A
- Average True Range (ATR)
- OTLK 0.10
- MGN 0.00
- MACD
- OTLK 0.07
- MGN 0.00
- Stochastic Oscillator
- OTLK 83.63
- MGN 0.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.